{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:41:15Z","timestamp":1772700075898,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,3,16]],"date-time":"2013-03-16T00:00:00Z","timestamp":1363392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1245\/s10434-013-2871-3","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T22:17:17Z","timestamp":1363385837000},"page":"2274-2278","source":"Crossref","is-referenced-by-count":43,"title":["Medical or Surgical Therapy for Primary Aldosteronism: Post-treatment Follow-up as a Surrogate Measure of Comparative Outcomes"],"prefix":"10.1245","volume":"20","author":[{"given":"G. A.","family":"Kline","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Pasieka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. C.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,16]]},"reference":[{"key":"2871_CR1","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293\u20133000.","journal-title":"J Am Coll Cardiol"},{"key":"2871_CR2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1507\/endocrj.KR-105","volume":"54","author":"T Nishikawa","year":"2007","unstructured":"Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? Endocrine J. 2007;54:487\u201395.","journal-title":"Endocrine J"},{"key":"2871_CR3","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1210\/jc.2009-1406","volume":"94","author":"S Alvarez-Madrazo","year":"2009","unstructured":"Alvarez-Madrazo S, Padmanabhan S, Mavosi BM, Watkins H, Avery P, Wallace AM, et al. Familial and phenotypic associations of the aldosterone\u2013renin ratio. J Clin Endocrinol Metab. 2009;94:4324\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"2871_CR4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1046\/j.1365-2265.2003.01817.x","volume":"59","author":"PL Padfield","year":"2003","unstructured":"Padfield, PL. Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice. Clin Endocrinol (Oxf). 2003;59:422\u20136.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2871_CR5","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","volume":"18","author":"A Mahmud","year":"2005","unstructured":"Mahmud A, Mahgoub M, Hall M, Feely J. Does aldosterone to renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens. 2005;18:1631\u201335.","journal-title":"Am J Hypertens"},{"key":"2871_CR6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","volume":"19","author":"M Sartori","year":"2006","unstructured":"Sartori M, Calo LA, Mascagna V, Realdi A, Macchini L, Ciccariello L, et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens. 2006;19:373\u20139.","journal-title":"Am J Hypertens"},{"key":"2871_CR7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/SLA.0b013e318165c075","volume":"247","author":"R Zarnegar","year":"2008","unstructured":"Zarnegar R, Young WF, Lee J, Sweet MP, Kebebew E, Farley DR, et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg. 2008;247:511\u20138.","journal-title":"Ann Surg"},{"key":"2871_CR8","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820\u20135.","journal-title":"Am J Cardiol"},{"key":"2871_CR9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","volume":"9","author":"A Karagiannis","year":"2008","unstructured":"Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9:509\u201315.","journal-title":"Expert Opin Pharmacother"},{"key":"2871_CR10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"Catena C, Colussi GL, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911\u20138.","journal-title":"Hypertension"},{"key":"2871_CR11","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1210\/jc.2011-0138","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab. 2011;96:2904\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"2871_CR12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s11255-008-9441-9","volume":"40","author":"GA Kline","year":"2008","unstructured":"Kline GA, Harvey A, Jones C, Hill MH, So B, Scott-Douglas N, et al. Adrenal vein sampling in primary aldosteronism: final diagnosis depends upon which interpretation rule is used. Int Urol Nephrol. 2008;40:1035\u201343.","journal-title":"Int Urol Nephrol"},{"key":"2871_CR13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/BF02067355","volume":"16","author":"G Favia","year":"1992","unstructured":"Favia G, Lumachi F, Scarpa V, D\u2019Amico DF. Adrenalectomy in primary aldosteronism: a long term follow up study in 52 patients. World J Surg. 1992;16:680\u20134.","journal-title":"World J Surg"},{"key":"2871_CR14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s002689900407","volume":"22","author":"J Siren","year":"1998","unstructured":"Siren J, Valimaki M, Huikuri K, Sivula A, Voutilainen P, Haapiainen R. Adrenalectomy for primary aldosteronism: long term follow up study in 29 patients. World J Surg. 1998;22:418\u201322.","journal-title":"World J Surg"},{"key":"2871_CR15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00268-004-7496-z","volume":"29","author":"A Meyer","year":"2005","unstructured":"Meyer A, Brabant G, Behrend M. Long term follow up after adrenalectomy for primary aldosteronism. World J Surg. 2005;29:155\u20139.","journal-title":"World J Surg"},{"key":"2871_CR16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi GL, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Int Med. 2008;168:80\u20135.","journal-title":"Arch Int Med"},{"key":"2871_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJMp1204516","volume":"367","author":"DC Radley","year":"2012","unstructured":"Radley DC, Schoen C. Geographic variation in access to care: the relationship with quality. N Engl J Med. 2012;367:3\u20136.","journal-title":"N Engl J Med"},{"key":"2871_CR18","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1046\/j.1365-2168.2002.02261.x","volume":"89","author":"M Sywak","year":"2002","unstructured":"Sywak M, Pasieka JL. Long term follow up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002;89:1587\u201393.","journal-title":"Br J Surg"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-2871-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-013-2871-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-2871-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T11:22:56Z","timestamp":1559647376000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-013-2871-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,16]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2871"],"URL":"https:\/\/doi.org\/10.1245\/s10434-013-2871-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,16]]}}}